Open AccessLuminex-Based Desensitization Protocols: The University of Wisconsin Initial Experience
Author(s) -
Silke V. Niederhaus,
Brenda Muth,
David Lorentzen,
Philip Y. Wai,
John D. Pirsch,
Milagros SamaniegoPicota,
Glen Leverson,
Anthony M. D’Alessandro,
Hans W. Sollinger,
Arjang Djamali
Publication year - 2011
Publication title -
transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.45
H-Index - 204
eISSN - 1534-6080
pISSN - 0041-1337
DOI - 10.1097/tp.0b013e31821c93bb
Subject(s) - thymoglobulin , medicine , kidney transplantation , panel reactive antibody , transplantation , plasmapheresis , gastroenterology , desensitization (medicine) , incidence (geometry) , kidney , urology , antibody , surgery , immunology , receptor , physics , optics
We have demonstrated that immunodominant donor-specific antibody (DSA) more than 100 mean fluorescence intensity (MFI) at the time of transplant is associated with a significantly higher risk of rejection. We now present short-term outcomes of DSA-based desensitization (DSZ) strategies in patients with a negative complement-dependent cytotoxicity crossmatch.